Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk Stock Slips
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.
Novo Nordisk CFO says 2025 sales could see high-teens percentage growth
Novo Nordisk's sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an analyst call following the release of third-quarter earnings on Wednesday.
Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
manilatimes
13m
Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
Bagsværd, Denmark, 8 November 2024 - Today,
Novo
Nordisk
A/S has entered into an agreement to purchase 6,311,250 B shares ...
2d
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
2h
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...
2d
Novo Nordisk expects high demand for its obesity drugs in India, says country head
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...
FierceBiotech
2d
Novo Nordisk discards kidney disease drug from $1.3B deal in wake of phase 3 fail
Novo
Nordisk
, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1 ...
1d
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...
4d
on MSN
Scientist behind Novo Nordisk's Ozempic, Wegovy started her career developing laundry detergent
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
San Francisco Examiner
1d
Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
“Honestly, I’m quite alarmed by what we see in the U.S. now,”
Novo
Nordisk
President and CEO Lars Fruergaard Jorgensen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
United States
Semaglutide
Wegovy
Ozempic
Denmark
Feedback